No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin.
A single-blind, placebo-controlled, cross-over trial investigating possible interactions between paroxetine, a serotonin re-uptake inhibitor, and carbamazepine (CBZ), valproate (VPA) and phenytoin (PHT) was carried out in 20 outpatients with epilepsy. Patients on long-term treatment with CBZ, VPA, or PHT were given a 7-day placebo treatment, followed by paroxetine co-treatment for 16 days. Side effects were infrequent and mild. Paroxetine caused no changes in the plasma concentrations and all values were within the recommended ranges. No changes in protein binding were found. Plasma concentrations of paroxetine at steady state (8-147 ng/ml) were in the normal range for a 30-mg daily dosing regimen. None of the patients experienced epileptic seizures during the study.
Andersen
B B
BB
University Clinic of Neurology, Hvidovre Hospital, Denmark.
Mikkelsen
M
M
Vesterager
A
A
Dam
M
M
Kristensen
H B
HB
Pedersen
B
B
Lund
J
J
Mengel
H
H
D000328:Adult; D000928:Antidepressive Agents / Q000494:pharmacology*; D002220:Carbamazepine / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017374:Paroxetine; D010672:Phenytoin / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D016037:Single-Blind Method; D014635:Valproic Acid / Q000494:pharmacology*
D000928:Antidepressive Agents; D010880:Piperidines; D002220:Carbamazepine; D017374:Paroxetine; D014635:Valproic Acid; D010672:Phenytoin